Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

October 1, 2020 3:00 PM - 4:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 10/1/2020 3:00:20 PM 10/1/2020 4:00:20 PM Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

Join us for an informative discussion on how COVID-19 has affected patient access to diagnoses, care, and innovative therapies. We’ve assembled an expert panel that will explore these important issues from an oncology perspective. Our forum - moderated by Robert K. Coughlin, President & CEO of MassBio - will feature the following speakers:

Dr. Meghan Mooradian, MD, Clinical Oncologist, Medical Oncology, Massachusetts General Hospital
Kirsten Sloan, Managing Director, Policy, American Cancer Society’s Cancer Action Network (ACS CAN)
Michelle Carrillo, Director, Advocacy Relations-Oncology, Amgen

The COVID-19 pandemic has had a profound, direct impact on Massachusetts, with over 121,000 total cases-to-date. However, as response and recovery continue, the ripple effects reveal a much broader public health impact. Our health care system has been shaken to its core, perhaps none more than the area of cancer care.

An American Cancer Society Cancer Action Network (ACS CAN) survey of cancer patients and survivors focused on COVID-19 effects uncovered that of those in active treatment, 79% reported delays to their health care. What does the patient’s path to diagnosis and treatment look like? Has cancer care adapted to meet these challenges? How is Massachusetts uniquely positioned to meet the moment? Our panel of experts will address these questions and more from their patient, oncologist, and innovator perspectives.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

This event is supported by Amgen

Webinar, click "live-stream" button to view

Michelle Carrillo
Director, Advocacy Relations, Amgen Oncology
Michelle Carrillo leads the US and Global Oncology Advocacy Relations organization for Amgen, and is responsible for developing and executing Amgen’s engagement strategy with patient organizations, professional societies and other key stakeholders in the oncology ecosystem. Michelle joined Amgen in June 2012 as Director of Government Affairs for the Intercontinental Region. In that role, Michelle helped expand Amgen’s presence in several countries, and advocated for policies promoting sustainable healthcare systems across the region. In 2017, Michelle joined the newly created US Advocacy Relations organization to launch a leading-edge approach to engaging the oncology advocacy community. Prior to Amgen, Michelle spent 6 years as a Director with the Office of the US Trade Representative, Executive Office of the President.
See All Sessions

Robert K. Coughlin
President & CEO, MassBio
As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them. Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries. He brings passion and energy to all of his endeavors.
See All Sessions

Meghan Mooradian, MD
Clinical Oncologist, Medical Oncology, Massachusetts General Hospital
Dr. Mooradian is a clinical investigator whose main area of interest is the study of the efficacy, toxicity and resistance patterns/mechanisms of immune therapeutics. At the Massachusetts General Hospital (MGH) Cancer Center, she is a member of the Thoracic and Cutaneous Oncology Centers. A key research effort of Dr Mooradian is to better define immune-related toxicities, characterize the patients that develop them and ultimately work to manage toxicity without abrogating anti-tumor efficacy. In addition to the study of immune-related toxicities, she is also invested in evaluating novel combination strategies to overcome resistance to immune checkpoint inhibitors. During the COVID-19 (CD-19) pandemic she has expanded her research to focus on C19-related outcomes in a cancer population and to understand how the pandemic has impacted the delivery of care in an oncologic practice. Dr. Mooradian graduated from the Boston University School of Medicine and then went on to medical residency at Beth Israel Deaconess Medical Center in Boston, MA. Prior to joining the Massachusetts General Hospital (MGH) Cancer Center faculty, she completed her hematology/oncology fellowship at the MGH/Dana Farber Cancer Center.
See All Sessions

Kirsten Sloan
Managing Director, Policy, American Cancer Society’s Cancer Action Network (ACS CAN)
Kirsten Sloan is Managing Director for Policy for the American Cancer Society’s Cancer Action Network (ACS CAN). In this capacity she manages a team of five senior policy principals and analysts with a focus on access to care, emerging science and prevention. Prior to joining ACS CAN, Kirsten was Vice President of the National Partnership for Women & Families with responsibility for the organization's multi-faceted health portfolio. Kirsten was also Director of Federal Health Issues for AARP. In that role, she served as chief health lobbyist and managed a team of senior lobbyists in AARP’s Government Relations Department. Kirsten and her team worked directly with Congress and the Administration on Medicare, prescription drugs, long-term care, Medicaid, and health insurance issues.
See All Sessions

Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

October 1, 2020 3:00 PM - 4:00 PM

Webinar, click "live-stream" button to view

Brought to you by